| Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line A Ciccullo, A Borghetti, LZ Dal Verme, A Tosoni, F Lombardi, M Garcovich, ... International journal of antimicrobial agents 56 (2), 106017, 2020 | 163 | 2020 |
| Incidence of deep vein thrombosis among non‐ICU patients hospitalized for COVID‐19 despite pharmacological thromboprophylaxis A Santoliquido, A Porfidia, A Nesci, G De Matteis, G Marrone, E Porceddu, ... Journal of Thrombosis and Haemostasis 18 (9), 2358-2363, 2020 | 122 | 2020 |
| GSDMB is increased in IBD and regulates epithelial restitution/repair independent of pyroptosis N Rana, G Privitera, HC Kondolf, K Bulek, S Lechuga, C De Salvo, ... Cell 185 (2), 283-298. e17, 2022 | 100 | 2022 |
| Predicting in‐hospital mortality in COVID‐19 older patients with specifically developed scores M Covino, G De Matteis, ML Burzo, A Russo, E Forte, A Carnicelli, ... Journal of the American Geriatrics Society 69 (1), 37-43, 2021 | 77 | 2021 |
| Assessment of neurological manifestations in hospitalized patients with COVID‐19 M Luigetti, R Iorio, AR Bentivoglio, L Tricoli, V Riso, J Marotta, C Piano, ... European journal of neurology 27 (11), 2322-2328, 2020 | 54 | 2020 |
| The thrilling journey of SARS-CoV-2 into the intestine: from pathogenesis to future clinical implications F Scaldaferri, G Ianiro, G Privitera, LR Lopetuso, LM Vetrone, V Petito, ... Inflammatory Bowel Diseases 26 (9), 1306-1314, 2020 | 52 | 2020 |
| Dual targeted therapy: a possible option for the management of refractory inflammatory bowel disease G Privitera, S Onali, D Pugliese, S Renna, E Savarino, A Viola, ... Journal of Crohn's and Colitis 15 (2), 335-339, 2021 | 50 | 2021 |
| COVID-19 and intestinal inflammation: Role of fecal calprotectin V Ojetti, A Saviano, M Covino, N Acampora, E Troiani, F Franceschi, ... Digestive and Liver Disease 52 (11), 1231-1233, 2020 | 49 | 2020 |
| Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: reorganisational response in a high-volume Italian … F Scaldaferri, D Pugliese, G Privitera, S Onali, LR Lopetuso, G Rizzatti, ... United European gastroenterology journal 8 (7), 775-781, 2020 | 48 | 2020 |
| Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease L Guidi, D Pugliese, TP Tonucci, L Bertani, F Costa, G Privitera, B Tolusso, ... United European gastroenterology journal 7 (9), 1189-1197, 2019 | 44 | 2019 |
| Combination therapy in inflammatory bowel disease–from traditional immunosuppressors towards the new paradigm of dual targeted therapy G Privitera, D Pugliese, S Onali, V Petito, F Scaldaferri, A Gasbarrini, ... Autoimmunity Reviews 20 (6), 102832, 2021 | 43 | 2021 |
| Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches G Privitera, D Pugliese, LR Lopetuso, F Scaldaferri, M Neri, L Guidi, ... Therapeutic advances in gastroenterology 14, 17562848211006669, 2021 | 40 | 2021 |
| Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational study L Goessens, JF Colombel, A Outtier, M Ferrante, J Sabino, C Judge, ... UEG Journal 9 (10), 1136-1147, 2021 | 29 | 2021 |
| Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study D Pugliese, G Privitera, F Crispino, N Mezzina, F Castiglione, G Fiorino, ... Alimentary pharmacology & therapeutics 56 (1), 95-109, 2022 | 27 | 2022 |
| Predictors and early markers of response to biological therapies in inflammatory bowel diseases G Privitera, D Pugliese, GL Rapaccini, A Gasbarrini, A Armuzzi, L Guidi Journal of clinical medicine 10 (4), 853, 2021 | 27 | 2021 |
| The enigmatic roles of epithelial gasdermin B: Recent discoveries and controversies AI Ivanov, N Rana, G Privitera, TT Pizarro Trends in cell biology 33 (1), 48-59, 2023 | 21 | 2023 |
| Novel insights into the interactions between the gut microbiome, inflammasomes, and gasdermins during colorectal cancer G Privitera, N Rana, F Scaldaferri, A Armuzzi, TT Pizarro Frontiers in Cellular and Infection Microbiology 11, 806680, 2022 | 21 | 2022 |
| Serum triiodothyronine‐to‐thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients L Bertani, D Tricò, D Pugliese, G Privitera, G Linsalata, F Zanzi, ... Alimentary Pharmacology & Therapeutics 53 (2), 273-280, 2021 | 21 | 2021 |
| The gasdermin protein family: emerging roles in gastrointestinal health and disease G Privitera, N Rana, A Armuzzi, TT Pizarro Nature Reviews Gastroenterology & Hepatology 20 (6), 366-387, 2023 | 19 | 2023 |
| Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey T Dionisi, L Sestito, C Tarli, M Antonelli, A Tosoni, S D’Addio, A Mirijello, ... International Journal of Clinical Practice 75 (11), e14755, 2021 | 19 | 2021 |
